Vilon is a synthetic peptide two amino acids long, the shortest kind of peptide chain. A dipeptide of that size is simple to make and simple to characterize, and it sits at the far end of a research program that began with natural extracts. It belongs to the peptide-bioregulator family, the short synthetic peptides that Vladimir Khavinson's group built around organ-specific animal tissue extracts [1][21]. Vilon is described as a thymomimetic, a peptide that mimics the activity of the thymus, the gland behind the breastbone where T cells mature [15]. It is not the natural extract itself: Thymalin is the calf-thymus peptide mixture, and Vilon is a separate synthetic peptide from the same laboratory [1].
Vilon was synthesized and named in a 1997 paper by Vladimir Morozov and Vladimir Khavinson at the Institute of Bioregulation and Gerontology in Saint Petersburg [1]. Their paper describes natural thymic peptides extracted from calf thymus with mild acid, the pharmaceutical called Thymalin, and the synthesis of the dipeptides Thymogen and Vilon [1]. Vilon is a synthesized dipeptide, so its length is the two amino acids themselves [1]. The thymus is the organ those natural peptides come from [1].
The research case for Vilon rests on three threads: immune signaling [1], immune aging [16], and the clotting changes that accompany type 1 diabetes [15]. The peptide has been given to patients in Russia as an addition to standard treatment, and the published reports describe coagulation and immune changes in diabetes and survival in older cancer patients [14][15][17]. It has also served as a laboratory tool for asking how a peptide this short can alter gene expression at all [11][22]. As of October 2026, Vilon is not on FDA's 503A bulks list and does not appear on FDA's Category 2 safety-risk table [26][27]. A ClinicalTrials.gov search on that date returned no registered study of Vilon.
Key takeaways
- Vilon is a two-amino-acid synthetic peptide from the Saint Petersburg thymic-peptide program, synthesized and named in 1997 [1].
- Laboratory studies report chromatin remodeling and shifts in SIRT1, PARP and NF-kB expression [11][20][22]. In mice and rats, Vilon reduced tumor development, but the direct molecular target is not established [2][3][6].
- Three Russian clinical reports describe use in type 1 diabetes and in older colorectal cancer patients, and none describes a placebo-controlled trial [14][15][17]. Vilon has no 503A listing [26], and no registered study of it appears on ClinicalTrials.gov.
How it works
The peptide-bioregulator idea: reaching DNA and chromatin
The main mechanistic idea in this literature is that Vilon enters cells and acts on chromatin, the packaged form of DNA, rather than on a receptor at the cell surface. A receptor is a protein on a cell membrane that a signal molecule docks with to start a response. Khavinson's group calls these short peptides bioregulators, and the proposal is that they act directly on gene regulation [11][22]. The idea is unusual, and the evidence for it is a mix of chromosome cytology, gene-expression measurements and computer modeling.
The clearest support comes from lymphocytes taken from older donors. In cultured lymphocytes from donors aged 75 to 88, Vilon unrolled heterochromatin, the tightly packed DNA that keeps genes silent, and reactivated ribosomal genes in the nucleolus organizer regions, the chromosome sites that hold the ribosomal RNA genes [11][16]. It did not decondense pericentromeric structural heterochromatin, the dense DNA around the chromosome centromere, while Epitalon and Livagen did in the same cultures [11][16]. These are cytological measurements: chromosome morphology and ribosomal gene activity, not sequencing of individual genes.
A 2023 study added a structural hypothesis. Molecular modeling suggested that the dipeptide can interact with GCGG sequences in B-form double-stranded DNA and with GGGC sequences in the curved DNA of a nucleosome, the spool of histone proteins that DNA wraps around [22]. Those sequences appear in the promoters of the human SIRT1, PARP1 and PARP2 genes, and a promoter is the DNA region that controls a gene's transcription [22]. The abstract reports molecular modeling only, with no measured binding constant, so the interaction is a model in that report [22].
Gene expression: SIRT1, PARP, IGF1 and NF-kB
In human mesenchymal stem cells, the support cells in bone marrow that build bone, fat and cartilage, Vilon changed the expression of genes tied to aging [22]. In replicatively aging cultures, Vilon raised SIRT1 gene expression 6-fold and SIRT1 protein 8.2-fold in the young cells, and lowered PARP1 expression 2.1-fold and protein 5.3-fold, plus PARP2 expression 2.1-fold and protein 4.7-fold during aging [22]. SIRT1 is a protein deacetylase that responds to energy stress and is studied as a longevity factor. PARP1 and PARP2 are enzymes that detect DNA breaks and attach poly-ADP-ribose chains to proteins.
A separate experiment in human embryo bone marrow stem cells found that nanomolar concentrations of three short peptides raised IGF1 expression 3.5-fold to 5.6-fold, and that Vilon raised FOXO1 about 2-fold in one aging model but not the other [20]. IGF1 is insulin-like growth factor 1, a growth signal; FOXO1 is a transcription factor that slows growth under stress. Vilon also stimulated NF-kB expression in both aging models, and NF-kB is the master switch for inflammatory genes [20]. The direction is not uniformly anti-inflammatory: NF-kB rose in that experiment [20], while cytokine release fell in macrophages [21].
In mouse heart, a DNA microarray covering 15,247 clones detected 36 clones whose expression changed more than 2-fold after Vilon, against 98 after Epithalon, in a screen where 300 clones changed in total [9]. A microarray measures the activity of thousands of genes at once, and a clone is one spotted gene fragment. The smaller number fits the claim that these peptides act on a narrow set of genes, though the study did not test whether the changes mattered for heart function [9].
Cytokines, T cells and macrophage signaling
Vilon's immune effects show up as changes in what immune cells release and how they mature. Cytokines are the small proteins immune cells use to coordinate a response, and interleukins are a subset of them. The 1997 paper reports that natural and synthetic thymic peptides, Vilon among them, activated T-cell differentiation, changed intracellular cyclic nucleotide levels, and altered interleukin-2 and interferon output from blood lymphocytes [1]. Cyclic nucleotides are small intracellular messengers, and T-cell differentiation is the process by which a stem cell becomes a helper or cytotoxic T cell.
A 2022 study put Vilon into a human monocyte cell line, THP-1, matured into macrophages. Macrophages are the immune cells that clear debris and direct inflammation. In macrophages activated with lipopolysaccharide, a bacterial membrane component used to trigger inflammation, Vilon was one of five peptides that lowered TNF-alpha and IL-6 in the culture medium, and the same experiment reported lower IL-17 [21]. TNF-alpha and IL-6 are pro-inflammatory cytokines, and IL-17 is a cytokine that recruits neutrophils.
The same study found that Vilon activated STAT1 phosphorylation, a step in the signaling chain that interferon and other cytokines use, while it had only a small effect on ERK1/2 phosphorylation, a kinase in the growth-signal cascade [21]. Phosphorylation is the addition of a phosphate group that turns a protein on. The authors suggested a receptor-independent route in which the peptide acts inside the cell on gene regulation [21]. That proposal fits the chromatin work but has not been shown directly for Vilon.
Mitochondria, ribosomes and programmed cell death
In senescent human thymic cells, Vilon raised mitochondrial staining 1.5-fold and lowered the ribosomal protein L7A by 15 percent [19]. Mitochondria are the organelles that make ATP, the cell's energy currency, and a MitoTracker dye reports mitochondrial staining, a marker of mitochondrial function. Ribosomes are the machines that build proteins, and L7A is a ribosomal protein whose expression rises as cells age in culture. The authors read the pattern as normalization of mitochondrial and ribosomal function in thymocytes, the immature T cells of the thymus [19].
Vilon also reduced programmed cell death. In rat spleen lymphocytes damaged by irradiation, Vilon inhibited apoptosis, the ordered self-destruction that follows DNA damage, and its effect was stronger than Epithalon's [4]. In rats given 6 Gy of whole-body gamma radiation, Vilon increased thymocyte proliferation and the proliferative potential of intestinal stem cells, which the authors linked to postradiation recovery of the thymus, spleen and duodenum [5]. A gray is the unit of absorbed radiation dose, and 6 Gy to the whole body is a severe exposure used to model acute radiation injury.
What has been studied in humans
The human record comes from Russian clinical reports. Three clinical reports describe Vilon given as an addition to standard treatment: two in patients with type 1 diabetes and one in older adults treated for stage III colorectal cancer [14][15][17]. None of the abstracts describes a control arm, a randomization method, or the number of patients, and no trial of Vilon appears on ClinicalTrials.gov as of October 2026. A 2020 Russian review also describes Vilon among the thymomimetic peptides used in dental and maxillofacial treatment, and it summarizes clinical use rather than reporting a new trial [23].
The 2006 diabetes study looked at blood clotting in patients whose type 1 diabetes had destabilized [15]. Those patients had accelerated clotting, lower antithrombin III and protein C, higher fibrinogen and soluble fibrin monomer complexes, and reduced fibrinolysis, the pattern of chronic disseminated intravascular coagulation, or DIC. DIC is a condition in which clotting activation consumes the proteins that control bleeding. Vilon reduced or abolished the DIC pattern, and the effect was weaker in older patients with severe disease [15].
The 2007 report followed with immune and clotting measures in older adults with type 1 diabetes [17]. Vilon raised antithrombin III and protein C, stimulated fibrinolysis, and normalized the levels of active T lymphocytes, B lymphocytes and IgA, an antibody class that guards mucosal surfaces. In most patients the amount of insulin needed to stabilize blood glucose fell, the authors reported [17]. The two diabetes papers come from the same group and may describe overlapping patients, which the abstracts do not clarify.
The cancer report covered older adults with stage III rectal or colon cancer treated with radical therapy, with Vilon added to the regimen [14]. The authors called the results preliminary and suggested that adding Vilon could increase 2-year survival, prevent postoperative and late complications and recurrences, and improve quality of life [14]. No survival percentages, group sizes or statistical tests appear in the abstract, so the size of any benefit is unknown.
What the human data can support is narrow. The reports describe changes in laboratory measures of clotting and immunity, and one describes clinical outcomes without numbers [14]. None of the abstracts reports a pharmacokinetic measurement, so blood and tissue exposure is unquantified. The open clinical question is whether the clotting and immune changes translate into fewer complications or longer survival in a controlled trial.
Lab and animal studies
The animal literature is broader than the human literature and comes almost entirely from the same Saint Petersburg network. A large thread is cancer. In female CBA mice, subcutaneous Vilon started at 6 months of age extended lifespan, increased physical activity and endurance, lowered body temperature, and prevented spontaneous tumors, with no unfavorable effects on development reported [3]. A separate mouse study reported that Vilon inhibited growth of spontaneous tumors and lengthened life [2].
In rats given N-butyl-N-(4-hydroxybutyl)nitrosamine, a carcinogen that targets the bladder lining, tumors developed in 56 percent of Vilon-treated animals and 75.5 percent of controls, and preneoplastic changes fell about 2-fold [6]. In mice carrying Lewis lung carcinoma, Vilon at 1 mg/kg lengthened survival [10]. The same study found the opposite when Vilon was given at the same time as cyclophosphamide, a cytotoxic chemotherapy drug: the combination shortened survival [10]. In spleen tissue culture, Vilon at 5 ng/mL stimulated apoptosis in both young and old rats and abolished the inhibitory effect of cyclophosphamide [10]. The authors suggested that the two should not be used synchronously, a caution that matters for any future adjuvant study.
Radiation was the other major test. In rats exposed to 6 Gy of whole-body gamma radiation, Vilon increased thymocyte proliferation and the proliferative potential of intestinal stem cells, which the authors linked to postradiation recovery of the thymus, spleen and duodenum [5]. In rats given repeated low-dose radiation and mercury near the maximum allowable concentration, Vilon normalized lymphocyte counts by day 30 and reduced morbidity over 15 months [13].
In aged Wistar rats, one month of oral Vilon raised maltase and alkaline phosphatase activity in the intestinal epithelium and dipeptidase activity in deeper layers, changes the authors read as improved barrier and trophic function [7]. It also increased passive and active glucose transport in inverted intestinal sacs [8]. In rats with experimental chronic renal failure, subcutaneous Vilon lowered serum TGF-beta1 and mesenteric microvascular permeability when measured 2 months after onset [12]. TGF-beta1 is a cytokine that drives scar formation, and microvascular permeability is how readily fluid leaks from small vessels.
The gene-expression and chromatin work is smaller and mostly descriptive. A heart microarray found 36 changed clones after Vilon against 98 after Epithalon [9]. The chromatin studies found reactivation of ribosomal genes in lymphocytes from donors aged 75 to 88 [11][16]. None of these experiments measured a clinical outcome. Many papers are in Russian, and most of the studies come from the Saint Petersburg institute or its collaborators. The 2022 macrophage study was a collaboration between the Saint Petersburg institute and a group in Chieti-Pescara, Italy [21].
The limits are structural. The animal work tests many endpoints, from tumor incidence to intestinal enzymes to kidney permeability, but the abstracts rarely report group sizes or doses, which makes the size of each effect hard to judge. That makes the preclinical record broad in scope and hard to weigh, and it is why the human reports carry so much weight in the story even though there are only three.
Research in detail
Clinical study measuring coagulation and fibrinolysis in patients given Vilon as an addition to standard treatment · Patients with type 1 diabetes at the stage of destabilization, including older patients and those with severe disease
Vilon reduced or abolished the laboratory pattern of chronic disseminated intravascular coagulation, and the effect was less pronounced in older patients with severe disease.
Evidence scope: English abstract reviewed; full text not read. The abstract does not describe group sizes, randomization, a control arm, dose or statistical analysis.
Clinical study of Vilon added to complex therapy, with immune subset and coagulation measures · Elderly patients with type 1 diabetes
Antithrombin III and protein C rose, fibrinolysis increased, active T lymphocytes, B lymphocytes and IgA normalized, and most patients needed less insulin to stabilize glucose.
Evidence scope: English abstract reviewed; full text not read. The abstract gives no group size, dose, control arm or follow-up duration, and the cohort may overlap the 2006 diabetes study.
Preliminary clinical study adding Vilon to radical treatment · Older adults with stage III rectal or colon cancer
The authors suggest that adding Vilon could increase 2-year survival, prevent postoperative and late complications and recurrences, and improve quality of life.
Evidence scope: English abstract reviewed; full text not read. The abstract gives no patient numbers, control group, survival figures or statistics, and the authors call the results preliminary.
History and where it stands today
Vilon's record runs from a 1997 synthesis paper through three clinical reports to an unfinished regulatory story.
- 1997Morozov and Khavinson reported the synthesis and naming of Vilon in the International Journal of Immunopharmacology, alongside the natural thymic extract Thymalin and the synthetic dipeptide Thymogen [1].
- 2000Two studies reported that Vilon inhibited spontaneous tumor growth and extended lifespan in mice [2][3], and a third reported that it inhibited irradiation-induced apoptosis in rat lymphocytes [4]. One of them dosed female CBA mice subcutaneously from 6 months of age and recorded higher physical activity, lower body temperature and a longer lifespan [3].
- 2001Vilon lowered carcinogen-induced bladder tumor incidence from 75.5 percent in controls to 56 percent [6]. In rats given 6 Gy whole-body radiation, it improved thymocyte and intestinal stem-cell recovery [5].
- 2002Oral Vilon for one month raised intestinal enzyme activity and glucose transport in aged rats, and a heart microarray showed it changed 36 gene clones [7][8][9].
- 2003In mice with Lewis lung carcinoma, Vilon at 1 mg/kg lengthened survival, but synchronous dosing with cyclophosphamide shortened it, a timing interaction the authors flagged [10].
- 2004Lezhava and colleagues reported that Vilon unrolled heterochromatin and reactivated ribosomal genes in lymphocytes from older donors, without decondensing pericentromeric heterochromatin [11].
- 2005 to 2007Russian clinicians published a preliminary cancer study in older colorectal patients and two reports in type 1 diabetes describing reduced disseminated intravascular coagulation, higher antithrombin III and protein C, and changes in lymphocyte subsets [14][15][17].
- 2013A review of the group's clinical studies listed Vilon among the peptide bioregulators used as geroprotectors, alongside Thymalin, Thymogen, Epithalamin, Prostatilen, Cortexin and Retinalamin [18].
- 2020 to 2023Human cell work tied Vilon to SIRT1, PARP1, PARP2, FOXO1 and NF-kB expression [20][22], and to mitochondrial and ribosomal markers in thymic cells [19]. The 2022 macrophage study reported lower TNF, IL-6 and IL-17 release [21].
- October 2026Vilon has no entry on the 503A bulks list at 21 CFR 216.23 and none on FDA's Category 2 safety-risk table [26][27]. No registered study of Vilon appears on ClinicalTrials.gov. WADA's 2026 list does not name it, and its S0 and S2 classes carry catch-all language [24]. The NCAA 2026-27 list does not name it either, and its peptide-hormone class bans chemically or pharmacologically related substances, as the NCAA page explains [25].
How it compares with related peptides
Thymalin is the natural peptide complex extracted from calf thymus, and Vilon is one of the short synthetic peptides built in the same program [1]. Thymalin is a natural peptide mixture, while Vilon is a single two-amino-acid chain, so the two differ in definition as much as in effect. Vilon is described as thymomimetic, meaning it mimics thymic activity, and a 2013 review lists the two side by side among peptide bioregulators [15][18].
Thymogen is the other synthetic dipeptide from the Saint Petersburg program, built from a single immunomodulatory molecule that was isolated from Thymalin before synthesis [1]. Both are two amino acids long and both were developed as immune agents, but Thymogen was derived from the natural extract, while Vilon was a new design [1]. The 2022 macrophage study tested both and reported that all five Khavinson peptides lowered TNF and IL-6, with differences in the kinase signals each triggered [21]. The Thymogen page covers that peptide's own record.
Epithalon is a tetrapeptide, four amino acids long, from the pineal branch of the same program [19][21]. The two are studied side by side: in cultured lymphocytes from older donors [16], in intestinal enzyme and absorption experiments in aged rats [7][8], and in a heart gene-expression microarray [9]. Vilon acted more strongly on apoptosis in irradiated lymphocytes, while Epithalon changed more genes in the heart screen, so the comparison shows that these short peptides have distinct profiles [4][9]. The Epithalon page follows the pineal side.
Side effects and safety signals
The safety record is thin, and most of what exists comes from animal dosing and from clinical reports that do not mention adverse events.
- None of the three clinical abstracts reports an adverse event: no side effect appears in the abstracts, which means the abstracts are silent rather than the record proven safe [14][15][17].
- Chronic subcutaneous dosing in female CBA mice from 6 months of age produced no unfavorable effects on development, and the authors called long-term administration safe in that model [3].
- In type 1 diabetes, Vilon lowered the amount of insulin needed to stabilize glucose in most patients, a metabolic shift that any future trial would need to track [17].
- Synchronous use with cyclophosphamide shortened survival in tumor-bearing mice, while Vilon alone lengthened it, so timing against cytotoxic drugs is an unresolved safety question [10].
- None of the clinical abstracts reports a pharmacokinetic measurement, so blood and tissue exposure is unquantified [14][15][17].
- No FDA safety assessment for Vilon appears on the compounding pages reviewed: it is absent from the Category 2 safety-risk table and from the 503A bulks list [26][27].
- Identity and purity are the practical checks for any research material, and the COA library collects the tests suppliers publish.
The future: what's next for Vilon
No registered trial of Vilon appears on ClinicalTrials.gov. A search on October 23, 2026 returned no study of Vilon, and the three published clinical reports date from 2005 to 2007 [14][15][17]. A modern study would need a randomized design, a defined dose and a clinical endpoint such as survival or complication rate, none of which the abstracts provide.
The regulatory picture is quiet. Vilon is not one of the six substances on the 503A bulks list, and it does not appear on FDA's Category 2 table of bulk substances that may present significant safety risks [26][27]. The sources reviewed show no FDA action on Vilon and no scheduled review, so there is no decision date to watch.
The science is moving toward mechanism rather than therapy. The 2023 modeling and stem-cell work asks how a dipeptide can dock on DNA and shift SIRT1 and PARP output, and the 2022 macrophage study asks which kinase pathways it touches [22][21]. Independent replication of the chromatin and gene-expression findings would matter more than another clinical series, because most of the mechanism work comes from one research network.
The diabetes question is the most tractable clinical opening. Disseminated intravascular coagulation is measurable, the 2006 and 2007 reports describe a consistent direction, and a randomized trial with antithrombin III, protein C, soluble fibrin monomer complexes and fibrinolysis as endpoints would test the claim directly [15][17].
- Does Vilon bind DNA directly inside cells, or is the modeled interaction with the SIRT1, PARP1 and PARP2 promoters a modeling artifact? [22]
- Which of the many gene-expression changes, from SIRT1 to NF-kB, actually drives the immune and clotting effects? [20][22]
- Can the coagulation and immune findings in type 1 diabetes be reproduced in a randomized trial outside the groups that published them? [15][17]
- Does giving Vilon at the same time as cytotoxic chemotherapy help or hurt, since the mouse survival data point both ways? [10]
- What blood and tissue levels follow the exposures used in the Russian reports, and how quickly is the peptide cleared? No human pharmacokinetic measurement appears in the clinical abstracts [14][15][17].